| Literature DB >> 33414788 |
Tatsuya Yamazaki1, Mrityunjoy Biswas1, Kouyu Kosugi2, Maria Nagashima2, Masanori Inui1, Susumu Tomono1, Hidekazu Takagi1, Isao Ichimonji1, Fumiaki Nagaoka1, Akira Ainai3, Hideki Hasegawa3, Joe Chiba2, Sachiko Akashi-Takamura1.
Abstract
Radioprotective 105 (RP105) (also termed CD180) is an orphan and unconventional Toll-like receptor (TLR) that lacks an intracellular signaling domain. The agonistic anti-RP105 monoclonal antibody (mAb) can cross-link RP105 on B cells, resulting in the proliferation and activation of B cells. Anti-RP105 mAb also has a potent adjuvant effect, providing higher levels of antigen-specific antibodies compared to alum. However, adjuvanticity is required for the covalent link between anti-RP105 mAb and the antigen. This is a possible obstacle to immunization due to the link between anti-RP105 mAb and some antigens, especially multi-transmembrane proteins. We have previously succeeded in inducing rapid and potent recombinant mAbs in mice using antibody gene-based delivery. To simplify the covalent link between anti-RP105 mAb and antigens, we generated genetic constructs of recombinant anti-RP105 mAb (αRP105) bound to the transmembrane domain of the IgG-B cell receptor (TM) (αRP105-TM), which could enable the anti-RP105 mAb to link the antigen via the cell membrane. We confirmed the expression of αRP105-TM and the antigen hemagglutinin, which is a membrane protein of the influenza virus, on the same cell. We also found that αRP105-TM could activate splenic B cells, including both mature and immature cells, depending on the cell surface RP105 in vitro. To evaluate the adjuvanticity of αRP105-TM, we conducted DNA immunization in mice with the plasmids encoding αRP105-TM and hemagglutinin, followed by challenge with an infection of a lethal dose of an influenza virus. We then obtained partially but significantly hemagglutinin-specific antibodies and observed protective effects against a lethal dose of influenza virus infection. The current αRP105-TM might provide adjuvanticity for a vaccine via a simple preparation of the expression plasmids encoding αRP105-TM and of that encoding the target antigen.Entities:
Keywords: DNA immunization; RP105; adjuvant; agonistic antibody; antibody gene-vector delivery; cell membrane; influenza; targeting antigen to B cells
Mesh:
Substances:
Year: 2020 PMID: 33414788 PMCID: PMC7783388 DOI: 10.3389/fimmu.2020.606518
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561